Skip to main content
Figure 2 | Virology Journal

Figure 2

From: Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity

Figure 2

Consistency in epitope specific antigenicity for clinical stage developmental lots ("C" lots) and commercial lots ("K" lots) as probed with a panel of mAbs. Four mAbs were employed to track the solution antigenicity of the various lots (see relative IC50 values in Table 2) to provide additional quantitative information on VLP epitopes, in addition to product release tests. The one standard deviations were plotted for clinical lots (n = 5) and for commercial lots (n = 4) to illustrate the tighter range of VLP solution antigenicity of commercial lots achieved as compared to clinical developmental lots.

Back to article page
\